Abstract

IntroductionOf the two million new HIV infections in adults in 2014, 70% occurred in sub-Saharan Africa. Several African countries have already approved guidelines for pre-exposure prophylaxis (PrEP) for individuals at substantial risk of HIV as part of combination HIV prevention but key questions remain about how to identify and deliver PrEP to those at greatest need. Throughout the continent, individuals in sero-discordant relationships, and members of key populations (sex workers, men who have sex with men (MSM), transgender women and injection drug users) are likely to benefit from the availability of PrEP. In addition, adolescent girls and young women (AGYW) are at substantial risk in some parts of the continent. It has been estimated that at least three million individuals in Africa are likely to be eligible for PrEP according to WHO's criteria. Tens of demonstration projects are planned or underway across the continent among a range of countries, populations and delivery settings.DiscussionIn each of the target populations, there are overarching issues related to (i) creating demand for PrEP, (ii) addressing supply-side issues and (iii) providing appropriate and tailored adherence support. Critical for creating demand for PrEP is the normalization of HIV prevention. Community-level interventions which engage opinion leaders as well as empowerment interventions for those at highest risk will be key. Critical to supply of PrEP is that services are accessible for all, including for stigmatized populations. Establishing accessible integrated services provides the opportunity to address other public health priorities including the unmet need for HIV testing, contraception and sexually transmitted infections treatment. National policies need to include minimum standards for training and quality assurance for PrEP implementation and to address supply chain issues. Adherence support needs to recognize that social and structural factors are likely to have an important influence. Combining interventions that build self-efficacy, empowerment and social cohesion, with evidence-based individualized adherence support for PrEP, are most likely to be effective.ConclusionsEfficacy of tenfovir-based PrEP is proven but many issues related to implementation remain unclear. Here, we have summarized some of the important implementation questions that need to be assessed as PrEP is rolled out across Africa.

Highlights

  • Of the two million new HIV infections in adults in 2014, 70% occurred in sub-Saharan Africa

  • Efficacy of tenfovir-based pre-exposure prophylaxis (PrEP) is proven but many issues related to implementation remain unclear

  • We have summarized some of the important implementation questions that need to be assessed as PrEP is rolled out across Africa

Read more

Summary

Discussion

In each of the populations discussed above, there are all, including stigmatized populations. Using existing technology, point-of-care urine assays for tenofovir are in development The cost of these assays will Research monitoring and evaluation likely range from $10 to $20 per test, which may be po- Implementation research is underway to determine how to tentially affordable for PrEP implementation programmes in take PrEP delivery to scale across Africa in a way that is some settings [68Á70]. Is it feasible to recruit side demand generated safely in improve risk sero-discordant.

Conclusions
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call